- Hecogenin
-
- $60.00
-
2026-04-22
- CAS:467-55-0
- Purity: 99.56%
- Supply Ability: 10g
- Hecogenin
-
- $1.00
-
2025-12-12
- CAS:467-55-0
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100000KG
- Hecogenin
-
-
2023-02-24
- CAS:467-55-0
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Hecogenin Basic information |
| Product Name: | Hecogenin | | Synonyms: | HECOGENIN;5-ALPHA, 20-ALPHA, 22-ALPHA, 25D-SPIROSTAN-3-BETA-OL-12-ONE;5ALPHA-SPIROSTAN-3BETA-OL-12-ONE;3BETA-HYDROXY-5ALPHA-SPIROSTAN-12-ONE;25R,5ALPHA-SPIROSTAN-3BETA-OL-12-ONE;Hecoginin;(25R)-5-Spirostan-3-ol-12-one;(3,5,25R)-3-Hydroxysiprostan-1 | | CAS: | 467-55-0 | | MF: | C27H42O4 | | MW: | 430.62 | | EINECS: | 207-392-4 | | Product Categories: | Biochemistry;Steroids (Others);Steroids;467-55-0 | | Mol File: | 467-55-0.mol |  |
| | Hecogenin Chemical Properties |
| Melting point | 268°C | | alpha | 7.2 º (c=0.8 g/100ml, CHCl3) | | Boiling point | 464.85°C (rough estimate) | | density | 1.0040 (rough estimate) | | refractive index | 1.4840 (estimate) | | storage temp. | Sealed in dry,Room Temperature | | solubility | Chloroform (Slightly), Methanol (Slightly) | | pka | 15.10±0.70(Predicted) | | form | Solid | | color | White to Off-White | | Merck | 14,4622 | | CAS DataBase Reference | 467-55-0(CAS DataBase Reference) |
| | Hecogenin Usage And Synthesis |
| Uses | antiinflammatory | | Uses | Hecogenin, is a sapogenin present in the leaves of species from the Agave genus, possessing wide spectrum of pharmacology activities, such as having antinociceptive properties. | | Definition | ChEBI: Hecogenin is a triterpenoid. | | in vivo | Hecogenin (3.1-90 mg/kg; oral administration; for 15 hours; male Swiss mice) acutely administered, before ethanol, exhibits a potent gastroprotective effect. The Hecogenin pretreatment normalizes GSH levels and significantly reduces lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Hecogenin also decreases MPO release and significantly protects the gastric mucosa[1]. | Animal Model: | Male Swiss mice (20-30 g) with ethanol[1] | | Dosage: | 3.1 mg/kg, 7.5 mg/kg, 15 mg/kg, 30 mg/kg, 60 mg/kg and 90 mg/kg | | Administration: | Oral administration; for 15 hours | | Result: | Normalized GSH levels and significantly reduced lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Decreased MPO release and significantly protected the gastric mucosa.
|
| | Purification Methods | The saponin (~35 mg) in EtOAc is chromatographed on Al2O3 and eluted with *C6H6/Et2O, and the residue on evaporation is recrystallised from Me2CO. [Mazur et al. J Am Chem Soc 82 5889 1960, Marker et al. J Am Chem Soc 69 2167 1947, Beilstein 19 III/IV 2581.] |
| | Hecogenin Preparation Products And Raw materials |
|